BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses 2017;9:E96. [PMID: 28468285 DOI: 10.3390/v9050096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Park E, Dezhbord M, Lee AR, Park BB, Kim K. Dysregulation of Liver Regeneration by Hepatitis B Virus Infection: Impact on Development of Hepatocellular Carcinoma. Cancers 2022;14:3566. [DOI: 10.3390/cancers14153566] [Reference Citation Analysis]
2 Goyal A, Ribeiro RM, Perelson AS. The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses 2017;9:E350. [PMID: 29156567 DOI: 10.3390/v9110350] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
3 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
4 Huang BY, Tsai MR, Hsu JK, Lin CY, Lin CL, Hu JT, Huang YW, Liu CJ, Wu WJ, Wu CF, Sung FY, Chen PJ, Liang HJ, Lin SM, Yu MW. Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. Mol Carcinog 2020;59:1269-79. [PMID: 32914490 DOI: 10.1002/mc.23255] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhang Z, Lu W, Zeng D, Huang D, Lin W, Yan L, Feng Y. Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J Clin Med 2021;10:5617. [PMID: 34884319 DOI: 10.3390/jcm10235617] [Reference Citation Analysis]
6 Wang Y, Wang J. Intravital Imaging of Inflammatory Response in Liver Disease. Front Cell Dev Biol 2022;10:922041. [DOI: 10.3389/fcell.2022.922041] [Reference Citation Analysis]
7 Javanbakht H, Mueller H, Walther J, Zhou X, Lopez A, Pattupara T, Blaising J, Pedersen L, Albæk N, Jackerott M, Shi T, Ploix C, Driessen W, Persson R, Ravn J, Young JAT, Ottosen S. Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo. Mol Ther Nucleic Acids 2018;11:441-54. [PMID: 29858079 DOI: 10.1016/j.omtn.2018.02.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
8 Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313-2324. [PMID: 30496122 DOI: 10.1016/s0140-6736(18)31865-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 62] [Article Influence: 46.3] [Reference Citation Analysis]
9 Pan XB, Lu YQ, Lin SZ, Ye J, Wu N, Lou YY, Ni L, Han JC, Zheng XQ, Wei L. An Assessment of Upper Limits of Normal for ALT and the Impact on Evaluating Natural Course of Chronic Hepatitis B Virus Infection in Chinese Children. Am J Gastroenterol 2018;113:1660-8. [PMID: 30353056 DOI: 10.1038/s41395-018-0248-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Schreiner S, Nassal M. A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond? Viruses 2017;9:E125. [PMID: 28531167 DOI: 10.3390/v9050125] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
11 Teng DK, Liu Y, Lv YF, Wang L, Zhang W, Wang JP, Li Y. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int Immunopharmacol 2019;70:252-9. [PMID: 30851705 DOI: 10.1016/j.intimp.2019.02.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
12 Yu W, Hu X, Cao B. Viral Infections During Pregnancy: The Big Challenge Threatening Maternal and Fetal Health. Maternal-Fetal Medicine 2022;4:72-86. [DOI: 10.1097/fm9.0000000000000133] [Reference Citation Analysis]
13 Shao X, Ma J, Jia S, Yang L, Wang W, Jin Z. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection. Front Cell Infect Microbiol 2017;7:472. [PMID: 29181338 DOI: 10.3389/fcimb.2017.00472] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
14 Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Sci. 2020;111:4218-4231. [PMID: 32889778 DOI: 10.1111/cas.14641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
16 Zhu S, Zhao P. Reply to: "Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues". J Hepatol 2018;69:981-2. [PMID: 30086997 DOI: 10.1016/j.jhep.2018.07.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Premkumar M, Chawla YK. Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia. Journal of Clinical and Experimental Hepatology 2022;12:144-54. [DOI: 10.1016/j.jceh.2021.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhu S, Zhang H, Dong Y, Wang L, Xu Z, Liu W, Gan Y, Tang H, Chen D, Wang F, Zhao P. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol. 2018;68:1123-1128. [PMID: 29452204 DOI: 10.1016/j.jhep.2018.01.037] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
19 Huang N, Ji FP, Zhang S, Li Z, Li J, Zhou R, Zhang S, Wei W, Li L, Chen H, Li B, Kong G, Yang J, Li Z. Spleen-Associated Effects on Immunity in Hepatitis B Virus-Related Cirrhosis with Portal Hypertension. J Interferon Cytokine Res 2019;39:95-105. [PMID: 30676849 DOI: 10.1089/jir.2018.0121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Freitas N, Lukash T, Gunewardena S, Chappell B, Slagle BL, Gudima SO. Relative Abundance of Integrant-Derived Viral RNAs in Infected Tissues Harvested from Chronic Hepatitis B Virus Carriers. J Virol. 2018;92. [PMID: 29491161 DOI: 10.1128/jvi.02221-17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
21 Pollicino T, Caminiti G. HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses 2021;13:368. [PMID: 33652619 DOI: 10.3390/v13030368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
23 Boettler T, Gill US, Allweiss L, Pollicino T, Tavis JE, Zoulim F. Assessing immunological and virological responses in the liver: implications for the cure of chronic hepatitis B virus infection. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100480] [Reference Citation Analysis]
24 Coffin CS, Schreiber RA. Hepatitis B in Children-The Pursuit of a Hepatitis Free Future Generation. J Pediatr 2021:S0022-3476(21)00684-3. [PMID: 34273356 DOI: 10.1016/j.jpeds.2021.07.017] [Reference Citation Analysis]
25 Martin P. Immune-Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat. Hepatology 2019;69:2315-7. [PMID: 30964209 DOI: 10.1002/hep.30654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Bollerup S, Hallager S, Baek O, Krarup H, Madsen LG, Thielsen P, Balslev U, Mens H, Barfod T, Rye Clausen M, Hobolth L, Gerstoft J, Weis N. Implementation of treatment recommendations for chronic hepatitis B in patients attending specialized hospital care in Denmark - a region wide study. Scand J Gastroenterol 2020;55:843-7. [PMID: 32568561 DOI: 10.1080/00365521.2020.1779803] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Yenilmez E, Cetinkaya RA. Are there optimal alanine aminotransferase and HBV DNA thresholds for discriminating HBeAg-positive chronic infection from chronic hepatitis? An evaluation of 215 young and male cases. Saudi Med J 2019;40:131-9. [PMID: 30723857 DOI: 10.15537/smj.2019.2.23934] [Reference Citation Analysis]
28 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 7.3] [Reference Citation Analysis]
29 Dolman GE, Koffas A, Mason WS, Kennedy PT. Why, who and when to start treatment for chronic hepatitis B infection. Curr Opin Virol. 2018;30:39-47. [PMID: 29655092 DOI: 10.1016/j.coviro.2018.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
30 Zhu S, Dong Y, Wang L, Liu W, Zhao P. Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. J Hepatol. 2019;71:871-875. [PMID: 31228491 DOI: 10.1016/j.jhep.2019.06.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
31 Vinikoor MJ, Sinkala E, Chihota B, Kanunga A, Wandeler G. Hepatitis B Therapy as HIV Prevention in Africa: A Case Series From Zambia. Hepatology 2019;69:458-60. [PMID: 30019488 DOI: 10.1002/hep.30183] [Reference Citation Analysis]
32 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
33 Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol 2018;30:32-8. [PMID: 29454995 DOI: 10.1016/j.coviro.2018.01.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
34 Koshiol J, Liu Z, O'Brien TR, Hildesheim A. Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. Cancer Epidemiol 2018;53:195-9. [PMID: 29396075 DOI: 10.1016/j.canep.2018.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Mason WS, Jilbert AR, Litwin S. Hepatitis B Virus DNA Integration and Clonal Expansion of Hepatocytes in the Chronically Infected Liver. Viruses 2021;13:210. [PMID: 33573130 DOI: 10.3390/v13020210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Wu H, Liao B, Li X, Liu H, Gong M, Shi H, Xie S, Guo F, Chen K, Yan R, Zhao H, Li L, Zheng A, Liu Y, Wang Z. Increased hepatitis B virus quasispecies diversity is correlated with liver fibrosis progression. Infect Genet Evol 2021;93:104938. [PMID: 34029727 DOI: 10.1016/j.meegid.2021.104938] [Reference Citation Analysis]
37 Maarouf M, Rai KR, Goraya MU, Chen JL. Immune Ecosystem of Virus-Infected Host Tissues. Int J Mol Sci 2018;19:E1379. [PMID: 29734779 DOI: 10.3390/ijms19051379] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
38 Zhang Z, Lu W, Huang D, Zhou X, Ding R, Li X, Wang Y, Lin W, Zeng D, Feng Y. Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection. Front Immunol 2022;13:944097. [DOI: 10.3389/fimmu.2022.944097] [Reference Citation Analysis]
39 Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21 Suppl 2:e25054. [PMID: 29633564 DOI: 10.1002/jia2.25054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]